Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis

• Market Cap: ₹72.04B
• Dividend Yield: 0.68%
• Average Volume (3M): 56.30K
• Price to Earnings (P/E): 56.3
• Beta (1Y): 0.41
• Revenue Growth: 22.36%
• EPS Growth: 52.00%
• Country: IN
• Employees: 1,693
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.03
• Shares Outstanding: 159,161,700
• 10 Day Avg. Volume: 44,587
• 30 Day Avg. Volume: 56,302
• PEG Ratio: 1.46
• Price to Book (P/B): 7.05
• Price to Sales (P/S): 5.61
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ₹508.00 ▲(12.24% Upside)

Thyrocare Technologies Ltd shows strong financial performance with robust revenue growth and efficient cash flow management, which are the primary drivers of the stock score. Technical analysis indicates a positive trend, though valuation metrics suggest the stock is priced at a premium. The absence of earnings call data and notable corporate events limits additional insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust market positioning and expanding service adoption, supporting long-term business sustainability.

Cash Flow Management

Effective cash flow management ensures operational efficiency and provides the company with the flexibility to make strategic investments.

Balance Sheet Health

A strong balance sheet with low debt levels minimizes financial risk and provides a stable foundation for future growth opportunities.

Negative Factors

Net Profit Margin Decline

A declining net profit margin may indicate rising costs or inefficiencies, which could impact profitability if not addressed.

Capital Expenditure Impact

High capital expenditures could strain liquidity, potentially limiting the company's ability to invest in growth or respond to market changes.

Operational Cost Optimization

Inefficiencies in cost management could erode margins and reduce competitiveness if not strategically addressed.

Thyrocare Technologies Ltd Business Overview & Revenue Model

Company Description

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

How the Company Makes Money

Thyrocare generates revenue primarily through its diagnostic testing services, which include a variety of blood tests, genetic tests, and health check-up packages. The company operates a B2B model, supplying services to hospitals, clinics, and healthcare providers, which constitutes a significant portion of its revenue. Additionally, Thyrocare offers direct-to-consumer services, where individuals can order tests online or through collection centers. The company benefits from economies of scale due to its centralized laboratory operations, allowing for lower costs per test and competitive pricing. Thyrocare also engages in partnerships with various healthcare organizations and insurance companies, which helps to broaden its customer base and enhance revenue streams. Key factors contributing to its earnings include a strong brand reputation, a broad service portfolio, and an increasing awareness of preventive healthcare among the population.

Thyrocare Technologies Ltd Financial Statement Overview

Summary

Thyrocare Technologies Ltd exhibits strong financial health with consistent revenue growth, solid profitability margins, and a stable balance sheet. The company effectively manages its cash flows, ensuring operational efficiency and strategic investments. While there are areas for improvement, such as optimizing operational costs and managing capital expenditures, the overall financial outlook is positive, supporting future growth and stability.

Income Statement

Thyrocare Technologies Ltd has demonstrated strong revenue growth with a significant increase from 2024 to 2025, indicating robust market positioning. The gross profit margin has improved, reflecting efficient cost management. However, the net profit margin has seen a slight decrease, suggesting increased operational costs or financial expenses. Overall, the income statement shows a healthy trajectory with some areas for cost optimization.

Balance Sheet

The company maintains a solid equity base with an improving equity ratio, indicating financial stability. The debt-to-equity ratio is low, which minimizes financial risk, although there is a small increase in total debt. Return on equity remains strong, highlighting effective use of shareholder funds. The balance sheet reflects a stable financial structure with room for leveraging growth opportunities.

Cash Flow

Operating cash flow has increased, supporting operational sustainability. The free cash flow growth rate is positive, indicating effective capital management. The operating cash flow to net income ratio suggests high-quality earnings. However, capital expenditure remains significant, which may impact future liquidity if not managed carefully. Overall, cash flow statements show a healthy cash position with strategic investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.23B	6.87B	5.72B	5.27B	5.89B	4.95B
Gross Profit	5.62B	4.96B	1.81B	3.63B	4.19B	3.31B
EBITDA	2.21B	2.04B	1.48B	1.31B	2.64B	1.84B
Net Income	1.06B	915.10M	707.60M	644.90M	1.76B	1.13B
Balance Sheet
Total Assets	0.00	6.93B	6.44B	6.33B	6.08B	5.46B
Cash, Cash Equivalents and Short-Term Investments	1.55B	1.92B	1.77B	1.51B	1.39B	1.18B
Total Debt	0.00	246.80M	423.40M	233.10M	207.00M	84.90M
Total Liabilities	-5.47B	1.46B	1.16B	975.00M	810.90M	1.19B
Stockholders Equity	5.47B	5.47B	5.27B	5.34B	5.27B	4.27B
Cash Flow
Free Cash Flow	0.00	1.46B	1.06B	856.60M	755.80M	877.70M
Operating Cash Flow	0.00	1.91B	1.68B	1.29B	1.13B	1.16B
Investing Cash Flow	0.00	-525.20M	-912.80M	-389.90M	-235.70M	-502.30M
Financing Cash Flow	0.00	-1.30B	-848.00M	-861.80M	-894.10M	-615.70M

Thyrocare Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 452.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 452.6 is above the 20-day moving average (MA) of 445.58, below the 50-day MA of 455.45, and above the 200-day MA of 371.28, indicating a neutral trend. The MACD of -4.26 indicates Negative momentum. The RSI at 50.74 is Neutral, neither overbought nor oversold. The STOCH value of 77.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.

Thyrocare Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹105.69B	69.76	―	0.20%	16.71%	13.92%
THYROCARE	69 Neutral	₹72.04B	56.33	―	0.68%	22.36%	52.00%
KRSNAA	62 Neutral	₹23.62B	27.85	―	0.38%	11.51%	21.56%
METROPOLIS	61 Neutral	₹97.81B	61.66	―	0.21%	15.41%	5.93%
MOREPENLAB	57 Neutral	₹22.79B	23.11	―	0.49%	-0.29%	-29.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Thyrocare Technologies Ltd Corporate Events

Thyrocare Technologies Boosts Shareholder Value with Bonus Share Allotment

Thyrocare Technologies Limited has announced the allotment of over 10.6 crore bonus equity shares, following a 2:1 ratio, effectively tripling its paid-up share capital. This strategic move is expected to enhance shareholder value and strengthen the company’s financial standing, reflecting its robust market positioning and commitment to rewarding its stakeholders.

Thyrocare Technologies Approves Key Resolutions to Boost Growth

Thyrocare Technologies Ltd announced the successful passing of several resolutions through a postal ballot, including an increase in authorized share capital, alterations to the Articles of Association, and the issuance of bonus shares. These resolutions, approved by the requisite majority, are expected to impact the company’s capital structure and governance, potentially enhancing shareholder value and positioning the company for future growth.

Thyrocare Announces 2:1 Bonus Share Issue

Thyrocare Technologies Ltd has announced a bonus issue of equity shares, with a record date set for November 28, 2025. Shareholders will receive two bonus shares for every one share held, with trading of the new shares commencing on December 2, 2025. This move is expected to enhance shareholder value and potentially strengthen the company’s market position.

Thyrocare Technologies Enhances Capital Structure with Key Amendments

Thyrocare Technologies Ltd has announced amendments to its Articles and Memorandum of Association, including an increase in authorized share capital to Rs. 300 crore. These changes, approved by a postal ballot, aim to enhance the company’s financial flexibility and shareholder value, potentially impacting its market positioning and stakeholder interests.

Thyrocare Technologies Announces Postal Ballot Notice Publication

Thyrocare Technologies Limited has announced the publication of a notice for a postal ballot in newspapers, as per regulatory requirements. This notice informs stakeholders about the completion of sending postal ballot notices and the e-voting period, which is also available on the company’s website.

Thyrocare Technologies Releases Earnings Call Transcript

Thyrocare Technologies Limited announced the release of the transcript from its earnings conference call held on October 14, 2025. This disclosure is in accordance with regulatory requirements and is available on the company’s website. The call involved discussions with analysts and investors, providing insights into the company’s financial performance and strategic direction. This release is significant for stakeholders as it offers transparency into the company’s operations and future outlook.

Thyrocare Technologies Releases Q2 2025 Financial Results

Thyrocare Technologies Ltd has released its unaudited financial results for the quarter and half-year ending September 30, 2025. The results were published in both Marathi and English newspapers, Navshakti and Business Standard, respectively. The publication of these results is in compliance with the SEBI Listing Regulations, and they are also available on the company’s website. This disclosure is significant for stakeholders as it provides insights into the company’s financial performance and operational efficiency during the specified period.